Correspondence 0001193125-24-104917 from Aldeyra Therapeutics, Inc. (ALDX) (CIK 0001341235) (ALDX)
Aldeyra Therapeutics, Inc. (ALDX) (CIK 0001341235)
Date: April 22, 2024 · CIK: 0001341235 · Accession: 0001193125-24-104917
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-277753
Letter
VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Washington, D.C. 20549 Attn: Doris Stacey Gama Re: Aldeyra Therapeutics, Inc. Registration Statement on Form S-3 (File No. 333-277753)
Dear Ms. Gama:
Pursuant to Rules 460 and 461 under the Securities Act of 1933, as amended, Aldeyra Therapeutics, Inc. (the “Company”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to make the above-referenced Registration Statement on Form S-3 effective at 4:00 p.m. Eastern Time on Wednesday, April 24, 2024 or as soon thereafter as practicable.
The Company hereby authorizes Keith Scherer of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP, counsel to the Company, to orally modify or withdraw this request for acceleration.
Please provide a copy of the Commission’s order declaring the Registration Statement effective to Keith Scherer at Gunderson Dettmer, One Marina Park Drive, Suite 900, Boston, MA 02210. If possible, please also send such order by email to the attention of Keith Scherer at kscherer@gunder.com.
Thank you for your attention on this matter.
Very truly yours,
Aldeyra Therapeutics, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP Aldeyra Therapeutics, Inc. 131 Hartwell Avenue Suite 320 Lexington, MA 02421 April 22, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F. Street N.E. Washington, D.C. 20549 Attn: Doris Stacey Gama Re: Aldeyra Therapeutics, Inc. Registration Statement on Form S-3 (File No. 333-277753) Dear Ms. Gama: Pursuant to Rules 460 and 461 under the Securities Act of 1933, as amended, Aldeyra Therapeutics, Inc. (the “Company”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to make the above-referenced Registration Statement on Form S-3 effective at 4:00 p.m. Eastern Time on Wednesday, April 24, 2024 or as soon thereafter as practicable. The Company hereby authorizes Keith Scherer of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP, counsel to the Company, to orally modify or withdraw this request for acceleration. Please provide a copy of the Commission’s order declaring the Registration Statement effective to Keith Scherer at Gunderson Dettmer, One Marina Park Drive, Suite 900, Boston, MA 02210. If possible, please also send such order by email to the attention of Keith Scherer at kscherer@gunder.com. Thank you for your attention on this matter. Very truly yours, Aldeyra Therapeutics, Inc. By: /s/ Todd C. Brady, M.D., Ph.D. Todd C. Brady, M.D., Ph.D. Chief Executive Officer cc: Keith Scherer, Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP